Quan Anh Vu
Plus aucun poste en cours
Fortune : 272 258 $ au 31/03/2024
Profil
Quan Anh Vu formerly worked at Baleena Bioscience, Inc., as Chief Executive Officer in 2021, Solganick & Co., Inc., as Managing Director from 2019 to 2021, Opiant Pharmaceuticals, Inc., as Vice President from 2016 to 2019, Ocugen, Inc., as Chief Financial, Accounting & Business Officer in 2023, and 180 Life Sciences Corp., as Chief Operating & Business Officer from 2021 to 2023.
Mr. Vu received his undergraduate degree from the University of California, Los Angeles.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
OCUGEN INC
0,06% | 06/03/2023 | 165 934 ( 0,06% ) | 272 132 $ | 31/03/2024 |
180 LIFE SCIENCES CORP.
0,01% | 18/12/2023 | 54 ( 0,01% ) | 126 $ | 31/03/2024 |
Anciens postes connus de Quan Anh Vu
| Sociétés | Poste | Fin |
|---|---|---|
| OCUGEN, INC. | Director of Finance/CFO | 14/08/2023 |
| 180 LIFE SCIENCES CORP. | Chief Operating Officer | 18/01/2023 |
| Solganick & Co., Inc. | Corporate Officer/Principal | 01/10/2021 |
| Baleena Bioscience, Inc. | Corporate Officer/Principal | 01/10/2021 |
| OPIANT PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/08/2019 |
Formation de Quan Anh Vu
| University of California, Los Angeles | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| OCUGEN, INC. | Health Technology |
| 180 LIFE SCIENCES CORP. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Opiant Pharmaceuticals, Inc.
 Opiant Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Richmond, VA. | Health Technology |
| Solganick & Co., Inc. | Finance |
| Baleena Bioscience, Inc. |
